Suppr超能文献

白癜风治疗的临床与分子方面。

Clinical and Molecular Aspects of Vitiligo Treatments.

机构信息

Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India.

出版信息

Int J Mol Sci. 2018 May 18;19(5):1509. doi: 10.3390/ijms19051509.

Abstract

Vitiligo is an asymptomatic but cosmetically disfiguring disorder that results in the formation of depigmented patches on skin and/or mucosae. Vitiligo can be segmental or non-segmental depending upon the morphology of the clinical involvement. It can also be classified as progressing or stable based on the activity of the disease. Further, the extent of involvement can be limited (localized disease) or extensive (generalized disease). The treatment of vitiligo therefore depends on the clinical classification/characteristics of the disease and usually comprises of 2 strategies. The first involves arresting the progression of active disease (to provide stability) in order to limit the area involved by depigmentation. The second strategy aims at repigmentation of the depigmented area. It is also important to maintain the disease in a stable phase and to prevent relapse. Accordingly, a holistic treatment approach for vitiligo should be individualistic and should take care of all these considerations. In this review, we shall discuss the vitiligo treatments and their important clinical and molecular aspects.

摘要

白癜风是一种无症状但影响美容的疾病,导致皮肤和/或粘膜出现色素脱失斑块。根据临床受累的形态,白癜风可以是节段性的或非节段性的。根据疾病的活动情况,它也可以分为进展期或稳定期。此外,受累的程度可以是有限的(局限性疾病)或广泛的(全身性疾病)。因此,白癜风的治疗取决于疾病的临床分类/特征,通常包括两种策略。第一种策略涉及阻止活动性疾病的进展(提供稳定性),以限制色素脱失所涉及的区域。第二种策略旨在使色素脱失区域重新着色。保持疾病处于稳定阶段并防止复发也很重要。因此,白癜风的整体治疗方法应该是个体化的,并应考虑到所有这些因素。在这篇综述中,我们将讨论白癜风的治疗方法及其重要的临床和分子方面。

相似文献

1
Clinical and Molecular Aspects of Vitiligo Treatments.
Int J Mol Sci. 2018 May 18;19(5):1509. doi: 10.3390/ijms19051509.
2
Vitiligo: Translational research and effective therapeutic strategies.
Pigment Cell Melanoma Res. 2021 Jul;34(4):814-826. doi: 10.1111/pcmr.12974. Epub 2021 Apr 5.
4
Vitiligo. Pathogenesis and treatment.
Am J Clin Dermatol. 2001;2(3):167-81. doi: 10.2165/00128071-200102030-00006.
5
Vitiligo treatment update.
Australas J Dermatol. 2015 May;56(2):85-92. doi: 10.1111/ajd.12256. Epub 2014 Dec 13.
6
Vitiligo: new and emerging treatments.
Dermatol Ther. 2008 Mar-Apr;21(2):110-7. doi: 10.1111/j.1529-8019.2008.00178.x.
7
Vitiligo: an update on current pharmacotherapy and future directions.
Expert Opin Pharmacother. 2012 Sep;13(13):1885-99. doi: 10.1517/14656566.2012.712113. Epub 2012 Jul 27.
10
Phototherapy for vitiligo: A narrative review on the clinical and molecular aspects, and recent literature.
Photodermatol Photoimmunol Photomed. 2024 May;40(3):e12968. doi: 10.1111/phpp.12968.

引用本文的文献

2
Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location.
Dermatol Ther (Heidelb). 2024 Jun;14(6):1633-1647. doi: 10.1007/s13555-024-01187-z. Epub 2024 Jun 2.
3
Antioxidant mechanisms of mesenchymal stem cells and their therapeutic potential in vitiligo.
Front Cell Dev Biol. 2023 Dec 21;11:1293101. doi: 10.3389/fcell.2023.1293101. eCollection 2023.
4
The First Live-Cell Based Product in The Iranian Drug List; ReColorCell®.
Cell J. 2023 Mar 7;25(3):212-214. doi: 10.22074/cellj.2023.1978336.1183.
5
The Promising Role of Chemokines in Vitiligo: From Oxidative Stress to the Autoimmune Response.
Oxid Med Cell Longev. 2022 Jan 19;2022:8796735. doi: 10.1155/2022/8796735. eCollection 2022.
7
Plant-Derived Compounds as Promising Therapeutics for Vitiligo.
Front Pharmacol. 2021 Nov 11;12:685116. doi: 10.3389/fphar.2021.685116. eCollection 2021.
8
Vitiligo: What's old, what's new.
Dermatol Reports. 2021 Sep 15;13(2):9142. doi: 10.4081/dr.2021.9142. eCollection 2021 Aug 1.
9
Strategies to Develop a Suitable Formulation for Inflammatory Skin Disease Treatment.
Int J Mol Sci. 2021 Jun 4;22(11):6078. doi: 10.3390/ijms22116078.
10
Dedifferentiation of human epidermal melanocytes in vitro by long-term trypsinization.
Cell Tissue Bank. 2021 Mar;22(1):67-75. doi: 10.1007/s10561-020-09866-9. Epub 2020 Sep 25.

本文引用的文献

2
Effect of Dickkopf1 on the senescence of melanocytes: in vitro study.
Arch Dermatol Res. 2018 May;310(4):343-350. doi: 10.1007/s00403-018-1820-1. Epub 2018 Feb 13.
3
Vitiligo Skin: Exploring the Dermal Compartment.
J Invest Dermatol. 2018 Feb;138(2):394-404. doi: 10.1016/j.jid.2017.06.033. Epub 2017 Oct 10.
4
Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3.
J Invest Dermatol. 2018 Feb;138(2):355-364. doi: 10.1016/j.jid.2017.08.038. Epub 2017 Sep 18.
5
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
J Am Acad Dermatol. 2017 Oct;77(4):675-682.e1. doi: 10.1016/j.jaad.2017.05.043. Epub 2017 Aug 18.
6
Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.
Clin Rev Allergy Immunol. 2018 Feb;54(1):52-67. doi: 10.1007/s12016-017-8622-7.
7
New discoveries in the pathogenesis and classification of vitiligo.
J Am Acad Dermatol. 2017 Jul;77(1):1-13. doi: 10.1016/j.jaad.2016.10.048.
8
Genetics of Vitiligo.
Dermatol Clin. 2017 Apr;35(2):245-255. doi: 10.1016/j.det.2016.11.013.
9
Phototherapy and Combination Therapies for Vitiligo.
Dermatol Clin. 2017 Apr;35(2):171-192. doi: 10.1016/j.det.2016.11.008.
10
Medical and Maintenance Treatments for Vitiligo.
Dermatol Clin. 2017 Apr;35(2):163-170. doi: 10.1016/j.det.2016.11.007.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验